Millennium Management
PMVP icon

Millennium Management’s PMV Pharmaceuticals PMVP Stock Holding History

Millennium Management’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,000
Closed -$870K – 6743
2022
Q4 		$870K Buy
+100,000
New +$1.07M ﹤0.01% 4296

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management's PMVP Position: Q3 2025 in Review

Millennium Management sold out of PMV Pharmaceuticals (PMVP) in Q3 2025, closing a stake of 23,995 shares — an estimated $25.4K sold.

Millennium Management first reported a position in PMVP in Q3 2020 and held it in 14 quarters. The position peaked at $1.91M in Q3 2022. 64 funds tracked by Wall St. Rank hold PMVP as of Q3 2025.

  • Millennium Management reported no remaining PMV Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Millennium Management sold 23,995 PMV Pharmaceuticals shares in Q3 2025, an estimated $25.4K.
  • Millennium Management first reported a position in PMV Pharmaceuticals in Q3 2020 and held it in 14 quarters.
  • Millennium Management's PMV Pharmaceuticals position peaked at $1.91M in Q3 2022.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2025.

Based on Millennium Management's 13F filing for Q3 2025, filed 14 Nov 2025.